In less than a decade, we have seen a revolution in the fields of hematology and oncology with the advent of immunotherapy, specifically the use of checkpoint inhibitor therapies (anti-PDL, anti-PDL1, and anti-CTLA4). These checkpoint inhibitors have been proven to be a groundbreaking approach for advanced cancers previously thought to be resistant to all other forms of treatments. However, the clinical experience for primary brain tumors is minimal and not yet standard changing. We will review the preclinical data and clinical experience to date for the use of checkpoint inhibitors and novel lymphocytic (T cell) activating immunotherapies for primary brain tumors.
|Title of host publication||Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy|
|Subtitle of host publication||Second Edition|
|Number of pages||12|
|State||Published - 24 Apr 2018|
- Checkpoint inhibitors
- Mutational burden
- T cell